BTK and B-cell chronic lymphocytic leukemia: While historical CIT combinations have allowed patients with CLL to achieve good responses formerly, targeted therapies (e.g., bruton tyrosine kinase and B-cell lymphoma-2 inhibitors) have impressive activity in high-risk genomic subgroups and have largely replaced the role of CIT for all patients with CLL in certain countries.